- Home
- PETS vs CGTX Comparison
PETS vs CGTX Comparison
Compare PETS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- CGTX
- Stock Information
- Founded
- PETS 1996
- CGTX 2007
- Country
- PETS United States
- CGTX United States
- Employees
- PETS N/A
- CGTX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- CGTX Health Care
- Exchange
- PETS Nasdaq
- CGTX Nasdaq
- Market Cap
- PETS 82.0M
- CGTX 79.3M
- IPO Year
- PETS N/A
- CGTX 2021
- Fundamental
- Price
- PETS $4.07
- CGTX $0.55
- Analyst Decision
- PETS Sell
- CGTX Buy
- Analyst Count
- PETS 2
- CGTX 6
- Target Price
- PETS $3.50
- CGTX $8.00
- AVG Volume (30 Days)
- PETS 182.6K
- CGTX 588.8K
- Earning Date
- PETS 11-06-2024
- CGTX 11-08-2024
- Dividend Yield
- PETS 29.41%
- CGTX N/A
- EPS Growth
- PETS N/A
- CGTX N/A
- EPS
- PETS N/A
- CGTX N/A
- Revenue
- PETS $270,772,000.00
- CGTX N/A
- Revenue This Year
- PETS N/A
- CGTX N/A
- Revenue Next Year
- PETS $3.27
- CGTX N/A
- P/E Ratio
- PETS N/A
- CGTX N/A
- Revenue Growth
- PETS 2.26
- CGTX N/A
- 52 Week Low
- PETS $2.90
- CGTX $0.34
- 52 Week High
- PETS $8.27
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- PETS 56.76
- CGTX 54.28
- Support Level
- PETS $3.78
- CGTX $0.50
- Resistance Level
- PETS $4.17
- CGTX $0.64
- Average True Range (ATR)
- PETS 0.18
- CGTX 0.07
- MACD
- PETS -0.01
- CGTX 0.02
- Stochastic Oscillator
- PETS 62.22
- CGTX 67.74
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.